New drug cocktail aims to tackle lung cancer brain metastases
NCT ID NCT07343479
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (Sac-TMT and a third-generation EGFR-TKI), with or without radiation, in 45 people with a specific type of advanced lung cancer (EGFR-mutated non-squamous NSCLC) that has spread to the brain and stopped responding to previous treatment. The goal is to see if this approach can control the cancer for at least 6 months. Participants will receive the drugs intravenously and by mouth, and some may also get radiation to the brain.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sac-TMT (a drug) combined with a third-generation EGFR-TKI (another drug), with or without radiotherapy
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of lung cancer that has spread to the brain and stopped responding to standard therapy.
- What could go wrong
- This is an early Phase 2 trial with only 45 participants, so results may not apply to everyone. The combination may cause side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo outsmart tough lung cancer?
- Can we predict frailty in serious illness? a large study investigates
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Drug duo aims to tackle tough lung cancers after first treatment fails
- Blood test may let cancer patients take safe breaks from immunotherapy